The Pharmacokinetic and Safety Profile of UCN-01 in Combination With Irinotecan in Solid Tumors (Primarily Lung, Ovarian and GI Cancers)
Phase of Trial: Phase I
Latest Information Update: 23 May 2018
At a glance
- Drugs UCN 01 (Primary) ; Irinotecan
- Indications Gastrointestinal cancer; Lung cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 23 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 May 2007 Status change
- 20 Feb 2007 Status changed form recruiting to in progress.